We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
- Authors
Ferraldeschi, R; Welti, J; Luo, J; Attard, G; de Bono, J S
- Abstract
Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. However, over time, most tumors become resistant to ADT. The view of castration-resistant prostate cancer (CRPC) has changed dramatically in the last several years. Progress in understanding the disease biology and mechanisms of castration resistance led to significant advancements and to paradigm shift in the treatment. Accumulating evidence showed that prostate cancers develop adaptive mechanisms for maintaining AR signaling to allow for survival and further evolution. The aim of this review is to summarize molecular mechanisms of castration resistance and provide an update in the development of novel agents and strategies to more effectively target the AR signaling pathway.
- Subjects
ANDROGEN receptors; CELLULAR signal transduction; ANDROGEN drugs; PROSTATE cancer treatment; METASTASIS
- Publication
Oncogene, 2015, Vol 34, Issue 14, p1745
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2014.115